Neurobo Pharmaceuticals Inc NRBO:NASDAQ

Last Price$0.47NASDAQ Previous Close - Last Trade as of 3:49PM ET 7/01/22

Today's Change-0.01(2.04%)
Bid (Size)$0.41 (10)
Ask (Size)$0.52 (3)
Day Low / High$0.46 - 0.51
Volume39.2 K

View Biotechnology IndustryPeer Comparison as of 07/01/2022


Neurobo Pharmaceuticals Inc ( NASDAQ )

Price: $0.47
Change: -0.01 (2.04%)
Volume: 39.2 K
3:49PM ET 7/01/2022

LogicBio Therapeutics Inc ( NASDAQ )

Price: $0.40
Change: +0.05 (13.16%)
Volume: 303.8 K
4:00PM ET 7/01/2022

Artelo Biosciences Inc ( NASDAQ )

Price: $0.31
Change: -0.007 (2.15%)
Volume: 205.4 K
4:00PM ET 7/01/2022

Hoth Therapeutics Inc ( NASDAQ )

Price: $0.42
Change: -0.004 (1.00%)
Volume: 259.3 K
4:00PM ET 7/01/2022

Protagenic Therapeutics Inc ( NASDAQ )

Price: $0.69
Change: -0.04 (5.30%)
Volume: 15.0 K
4:00PM ET 7/01/2022

Read more news Recent News

Top Premarket Gainers
7:55AM ET 1/04/2022 MT Newswires

Allena Pharmaceuticals (ALNA) shares surged 32% on positive trial data for a treatment candidate for hyperuricemia and gout. NeuroBO Pharmaceuticals (NRBO)...

NeuroBo Pharmaceuticals Says Panel Recommends Continuing COVID-19 Drug Candidate Trial
9:17AM ET 10/13/2021 MT Newswires

NeuroBo Pharmaceuticals (NRBO) said Wednesday that an independent Data Monitoring Committee recommended the continuation of the company's phase 2/3...

NeuroBo Pharmaceuticals Raises $12.7 Million from Securities Offering
2:08PM ET 10/05/2021 MT Newswires

NeuroBo Pharmaceuticals (NRBO) said Tuesday it has sold about 4.3 million shares at $3.25 each, raising around $12.7 million for working capital, capital...

Top Midday Decliners
1:40PM ET 10/01/2021 MT Newswires

Omeros (OMER) said the US Food and Drug Administration has identified certain deficiencies in a review of its biologics license application for narsoplimab...

Company Profile

Business DescriptionNeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Boston, MA. View company web site for more details
Address200 Berkeley Street
Boston, Massachusetts 02116
Number of Employees9
Recent SEC Filing06/13/20224
President, Chief Executive & Medical OfficerBen Gil Price
Senior Vice President-OperationsMatthew Bardin
CFO, Secretary, Treasurer & DirectorRichard Kang
Senior Vice PresidentAndrew Bartynski

Company Highlights

Price Open$0.47
Previous Close$0.48
52 Week Range$0.37 - 5.63
Market Capitalization$12.5 M
Shares Outstanding26.7 M
SectorHealth Technology
Next Earnings Announcement08/15/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.61
Beta vs. S&P 500N/A
Net Profit MarginN/A
Return on Equity-140.86%

Analyst Ratings as of 07/22/2020

Consensus RecommendationConsensus Icon
Powered by Factset